Carmustine (Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius))

Overview

Carmustine is an alkylating agent used in the treatment of various malignancies, including brain tumours and multiple myeloma, among others.

Mechanism of Action

Carmustine causes cross-links in DNA and RNA, leading to the inhibition of DNA synthesis, RNA production and RNA translation (protein synthesis). Carmustine also binds to and modifies (carbamoylates) glutathione reductase. This leads to cell death.

Indications

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

• Astrocytoma
• Brain Stem Gliomas
• Ependymoma
• High Grade Glioma: Glioblastoma (GBM)
• Medulloblastomas
• Metastatic Brain Tumors
• Mycosis Fungoides (MF)
• Newly Diagnosed High-Grade Glioma
• Recurrent Glioblastoma Multiforme (GBM)
• Refractory Hodgkin Lymphoma
• Refractory Multiple Myeloma
• Refractory Non-Hodgkin's lymphoma